Polypoidal choroidal vasculopathy-an important diagnosis to make with therapeutic implications

Retina

Volumn 32, Issue 8, 2012, Pages 1446-1448

  Kokame, Gregg T ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b STRAUB CLINIC AND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC THERAPY; DRUG MEGADOSE; EDITORIAL; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA FLUORESCEIN ANGIOGRAPHY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID DISEASES; FEMALE; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYPS; PORPHYRINS;

EID: 84865755047     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182695bf8     Document Type: Editorial

References (26)

1. Yannuzzi LA, Sorensen J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy. Retina 1990;10:1-8.
2. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;115:478-485. (Pubitemid 27172703)
3. Laude A, Cackett PD, Vithana E, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 2010:29: 19-29.
4. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995;15:100-110.
5. Cohen S, Dubois L, Quentel G, Gaudric A. Editorial. Is indocyanine green angiography still relevant? Retina 2011;31:209-221.
6. Scassellati-Sforzolini B, Mariotti C, Bryan R, et al. Polypoidal choroidal vasculopathy in Italy. Retina 2001;21:121-125. (Pubitemid 32298769)
7. Khan S, Engelbert M, Imamura Y, Freund KB. Polypoidal choroidal vasculopathy-simultaneous indocyanine green angiography and eye-tracked spectral domain optical coher-ence tomography findings. Retina 2012;32:1057-1068.
8. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15-22.
9. Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol 2007;245:1441-1445. (Pubitemid 47423325)
10. Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004;49:25-37. (Pubitemid 38056622)
11. Freund KB, Zweifel SA, Engelbert M. Editorial. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010;30:1333-1349.
12. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994;118:258-298.
13. Rosa RH, Davis JL, Eifrig CW. Clinicopathologic correlation of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 2002;102:502-508. (Pubitemid 34727825)
14. Lafaut BA, Aisenbrey S, Van den Broecke C, et al. Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: a clinicopathologic correlation. Retina 2000;20:650-654. (Pubitemid 32427983)
15. Kameda T, Tsujikawa A, Otani A, et al. Polypoidal choroidal vasculopathy examined with en face optical coherence tomography. Clin Experiment Ophthalmol 2007;35:596-601. (Pubitemid 47491215)
16. Koh A, Lee WK, Chen LJ, et al. EVEREST Study: efficacy and safety of verteporfin photodynamic therapy with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012;32:1453-1464.
17. Gomi F, Sawa M, Sakaguchi H, et al. Effect of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70-73.
18. Lee SY, Kim JG, Joe SG, et al. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 2008;22:92-99.
19. Stangos AN, Gandhi JS, Nair-Sahni J, et al. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150:666-673.
20. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148: 70-78.
21. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6 month results. Br J Ophthalmol 2010;94:297-301.
22. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
23. Yamashiro K, Tomita K, Tsujikawa A, et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012. Epub ahead of print.
24. Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol 2008;19:208-212. (Pubitemid 351535916)
25. Jalil A, Mercieca K, Chaudhry NL, Stanga PE. Choroidal nonperfusion with significant subretinal exudation after PDT of predominantly classic CNV: an OCT and FFA study. Eur J Ophthalmol 2009;19:490-493.
26. Isola V, Pece A, Parodi MB. Chroroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol 2006;142:680-683. (Pubitemid 44442046)